Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine Inc. (MNMD) is a clinical-stage biotech company pioneering research into psychedelic-inspired therapies for mental health disorders. This dedicated news hub provides investors and researchers with timely updates on MNMD's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases detailing clinical trial progress, partnership announcements with leading research institutions, and analyses of the company's novel approaches to treating conditions like addiction and depression. Our curated collection ensures you stay informed about MNMD's work developing therapies that target neuroplasticity through compounds such as LSD-analogs and psilocybin derivatives.
Key updates include Phase 2 trial results, intellectual property developments, executive leadership changes, and presentations at major medical conferences. All content is sourced from verified channels to maintain compliance with financial disclosure standards.
Bookmark this page for streamlined access to MNMD's evolving story in psychedelic medicine. Check regularly for critical updates about FDA-regulated research programs and breakthrough therapy designation tracking within this emerging biopharmaceutical sector.
MindMed, a clinical-stage biopharmaceutical company, revealed that its management team will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference. This event takes place on June 27, 2024. The presentation will be accessible via a webcast on MindMed’s Investor Relations website starting at 7:00 AM ET on the same date. The webcast will remain available for replay for up to 90 days post-event.
MindMed has completed its End-of-Phase 2 meeting with the FDA for MM120, intended for treating Generalized Anxiety Disorder (GAD).
The FDA has aligned with MindMed on the requirements for Phase 3 clinical trials, set to begin in the second half of 2024.
The Phase 2b trial of MM120 showed significant results with a 65% clinical response rate and 48% clinical remission rate at Week 12.
MM120 was generally well-tolerated, with adverse events being mild to moderate and transient.
This advancement marks a important milestone for MindMed and the millions affected by GAD globally.
MindMed (NASDAQ: MNMD), a clinical stage biopharmaceutical company focusing on brain health disorders, announced its participation in two significant June conferences. The first is the BIO International Convention 2024 in San Diego, CA, where they will join the panel 'Challenging Biotech’s One-Track Mind When it Comes to Neuropsychiatric Drug Innovation' on June 4, 2024. The second is the Jefferies 2024 Global Healthcare Conference in New York, NY, where they will engage in 1x1 investor meetings on June 5-6, 2024.
MindMed, a clinical stage biopharmaceutical company (NASDAQ: MNMD), will participate in investor conferences in May, including the 2024 RBCCM Global Healthcare Conference and HCW's 2nd Annual BioConnect Investor Conference. Members of the management team will engage in fireside chats and 1x1 investor meetings to discuss novel product candidates for brain health disorders.
MindMed presented new studies at ISPOR 24 revealing the significant impact of Generalized Anxiety Disorder (GAD) in the US. The studies showed that GAD diagnosis increases healthcare costs, decreases work productivity, and diminishes health-related quality of life. Undiagnosed GAD patients incur even higher healthcare costs. MindMed is investigating new treatments for GAD and other brain health disorders.
MindMed reported positive Phase 2b clinical trial results for MM120 in Generalized Anxiety Disorder (GAD), receiving Breakthrough Therapy Designation from the FDA. Cash and cash equivalents were $252.3 million as of March 31, 2024. The Company is on track to initiate its Phase 3 program for MM120 in GAD in the second half of 2024. MindMed completed a $175.0 million offering, delisted from Cboe Canada, and continues trading on Nasdaq under the symbol 'MNMD'. The Company announced favorable results for MM120 and MM402 programs, with detailed plans and updates on clinical trials and FDA meetings.
MindMed presented Phase 2b study data of MM120 for Generalized Anxiety Disorder (GAD) at the APA Annual Meeting in New York. MM120 showed significant efficacy compared to placebo, with rapid and durable improvements in anxiety symptoms sustained for 12 weeks after a single dose. The study demonstrated a 65% clinical response rate and a 48% clinical remission rate. MM120 also improved depressive symptoms and was well-tolerated with mild to moderate adverse events. New epidemiology studies quantified the burden of GAD in the US.
MindMed, a clinical stage biopharmaceutical company, will host a conference call on May 8, 2024, to discuss first quarter financial results. The company is focused on developing novel treatments for brain health disorders.
FAQ
What is the current stock price of Mind Medicine (MNMD)?
What is the market cap of Mind Medicine (MNMD)?
